Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030369 | 0.86 | MAPT (0.45) | MAPTLMNAKMT2AMEN1KDM4E | |
| SCHEMBL29151258 | 0.85 | TDP1 (0.43) | MAPTLMNAKMT2ARAB9AALDH1A1 | |
| SCHEMBL29151342 | 0.84 | HTT (0.47) | MAPTLMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL27096956 | 0.80 | MAPT (0.48) | MAPTLMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL27096888 | 0.79 | MAPT (0.48) | MAPTLMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4033106 | 0.79 | RAB9A (0.49) | MAPTLMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4825951 | 0.78 | LMNA (0.61) | MAPTLMNAKMT2ARAB9AMEN1 | |
| SCHEMBL30218362 | 0.78 | MAPT (0.58) | MAPTLMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL21835362 | 0.78 | MAPT (0.52) | MAPTLMNAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL29780767 | 0.78 | MAPT (0.58) | MAPTLMNAHPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1802633-B1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-7750017-B2 | Heterocycles | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750017-B2 | Heterocycles | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20080132497-A1 | Novel Heterocycles | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132497-A1 | Novel Heterocycles | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2005007083-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | MAPT 4763/4885LMNA 850/4885HPGD 71/4885 |
| US-20080132497-A1 | Novel Heterocycles | HRAS, CCNC, PCNA | MAPT 4019/4885LMNA 761/4885HPGD 98/4885 |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | EGFR, ERBB2, ERBB3 | MAPT 4295/4885LMNA 3400/4885HPGD 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.